Teru Hideshima
Harvard University(US)Dana-Farber Cancer Institute(US)
Publications by Year
Research Areas
Multiple Myeloma Research and Treatments, Protein Degradation and Inhibitors, Peptidase Inhibition and Analysis, Ubiquitin and proteasome pathways, Histone Deacetylase Inhibitors Research
Most-Cited Works
- → A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma(2003)2,633 cited
- The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.(2001)
- → Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets(2007)926 cited
- → Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma(2001)904 cited
- → NF-κB as a Therapeutic Target in Multiple Myeloma(2002)892 cited
- → Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy(2000)858 cited
- → Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma